/Press Releases

Forge Therapeutics and Evotec present efficacy data for LpxC Inhibitor in urinary tract, lung, thigh, and abdominal infection models at ASM ESCMID 2017

San Diego, California, September 7, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced new preclinical data [...]

2017-10-06T18:31:58+00:00September 7th, 2017|

Forge Therapeutics and Evotec to present preclinical data on novel antibiotic program at 2017 ASM/ESCMID Conference

San Diego, California, August 29, 2017 – Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the [...]

2017-10-04T14:17:29+00:00August 29th, 2017|

Forge Therapeutics forms scientific advisory board with world renowned antibiotic and drug development experts

San Diego, California, July 26, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-09T22:00:57+00:00July 25th, 2017|

Forge and Evotec Present First Efficacy Data for LpxC Inhibitor in UTI Model at ASM Microbe 2017

San Diego, California, June 3, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-11T16:19:13+00:00June 3rd, 2017|

Forge Therapeutics to present new data on novel Gram-negative antibiotic program at ASM Microbe 2017

San Diego, California, May 24, 2017 – Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-09T17:08:34+00:00May 24th, 2017|

Forge Therapeutics raises $15m Series A financing to develop first novel Gram-negative antibiotic in decades

Series A Complements Recent CARB-X Non-Dilutive Funding Forge Is Resourced And Financed Into The Clinic  San Diego, California, April 25, 2017 – Forge [...]

2017-10-11T16:20:04+00:00April 25th, 2017|

Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’

San Diego, Calif., March 30, 2017 – Forge Therapeutics, Inc., (“Forge”), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, [...]

2017-10-09T22:04:13+00:00March 30th, 2017|
Load More Posts